Skip to main content

Bharat Neeti

BHARAT NEETI

Be Ahead With Economy And Policy Updates

192x192 - PWA

BHARAT NEETI

Be Ahead With Economy And Policy Updates

IGI Submits ISB 2301 IND Application to U.S. FDA for Solid Tumor Treatment

IGI Submits ISB 2301 IND Application to U.S. FDA for Solid Tumor Treatment
Ichnos Glenmark Innovation
WhatsApp
Copy link
URL has been copied successfully!
New York: Ichnos Glenmark Innovation, Inc. (IGI), a global clinical stage biotechnology company focused on developing Multispecific™ therapeutics in oncology, on Tuesday announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ISB 2301.

ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumor-associated antigens and engage both T cells and NK cells. This pentaspecific molecule combines five binding specificities: three tumor-associated antigens, plus T-cell and NK-cell activation. By combining tumor-cell recognition with complementary immune activity, ISB 2301 is being developed to address biological heterogeneity and immune-suppressive features of solid tumors.

“Submission of the IND for ISB 2301 marks an important milestone in advancing IGI’s multispecific oncology pipeline into clinical development,” said Lida Pacaud, M.D., President and Chief Executive Officer, IGI. “This pentaspecific candidate is designed to integrate multiple tumor targeting and immune-engaging functions within a single molecule. Our preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, a candidate we believe to be highly differentiated from current approaches. We plan to initiate a Phase 1 clinical trial of ISB 2301 in patients with solid tumors in 2027.”

ISB 2301 was engineered using IGI’s proprietary BEAT® Multispecific Platform and is designed to recognize three tumor-associated antigens while engaging both T cells and NK cells through complementary mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition, and the induction of a sustained type 1 immune response.

In preclinical studies, ISB 2301 demonstrated favorable pharmacokinetic and tolerability profiles in non-human primates, supporting the planned evaluation of its safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity in patients with advanced solid tumors.

Leave a Reply

Your email address will not be published. Required fields are marked *

You are warmly welcomed to India’s first On-Demand News Platform. We are dedicated to fostering a democracy that encourage diverse opinions and are committed to publishing news for all segments of the society. If you believe certain issues or news stories are overlooked by mainstream media, please write to us. We will ensure your news is published on our platform. Your support would be greatly appreciated if you could provide any relevant facts, images, or videos related to your issue.

Contact Form Demo